The record
Written from the 1 report below. Nothing here is unsourced.
- Health officials in the Democratic Republic of Congo are planning a small phase-2 clinical trial to test whether Merck's licensed Ervebo vaccine, followed by an experimental IAVI Sudan Ebola vaccine, can offer partial protection against the Bundibugyo Ebola strain to frontline health workers.
- Africa CDC, working with Médecins Sans Frontières and other partners, expects to submit the study design for clearance, and the trial could begin within two weeks with regulatory and ethical approval.
- At least 121 health workers and responders have been infected in the outbreak, 36 of whom have died, while strain-specific Bundibugyo vaccines remain months away.
- WHO supports such a study in a controlled research setting but advises against broader use of Ervebo against Bundibugyo because evidence of cross-protection remains limited.
What to watch next
- Whether Africa CDC's executive committee clears the study design and regulators grant ethical approval, allowing the trial to start within two weeks.
- Whether the initial $500,000 from Africa CDC and additional partner funding are secured to launch the study.
- What safety and immune-response data emerge, and whether further studies are needed to confirm protection against infection, severe disease, or death.
Coverage1
1 report
English national1
All filed from India
Named Congo - Kinshasa · Rwanda · Uganda · Bunia · Democratic Republic of Congo · Africa Centres for Disease Control and Prevention · Armand Sprecher · Arthur Caplan · Ervebo · International AIDS Vaccine Initiative · Mark Feinberg · Médecins Sans Frontières · Merck & Co. · NYU Grossman School of Medicine
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.